MD Biosciences

We are excited to attend the IASP 2024 World Congress on Pain from August 5-9 this year! If you are attending and would like to schedule a meeting with us, please reach out via email at [email protected]. We look forward to connecting!

We are excited to invite you to an upcoming webinar focused on the post-operative translational model. In this webinar, we will explore the challenges in developing new post-surgical pain agents, the use of preclinical animal models for surgical pain, and a success story of translating the pig post-operative pain model to the clinic.

Register here today: https://hubs.ly/Q02HGhq90

Exciting update from the Swine in Biomedical Research Conference 2024! 🌟 We presented our newest model for evaluating nerve repair technologies in large animals with our poster, "Post Surgical Pain Model in Swine: New Findings". Our study explores behavioral assessments, immunohistochemistry, and s*x differences to enhance pain management strategies in large animal models. We are looking forward to advancing these strategies further!

View the poster here to explore our latest advancements in translational research: https://hubs.la/Q02DplC80

Explore our diverse array of Parkinson's Disease models, including 6OHDA and MPTP rodent models, as well as neurodegeneration screening assays. We continue to further our understanding of the pathological processes underlying PD and provide effective systems for assessing therapeutic interventions. Download our datasheet to learn more! https://hubs.la/Q02BJHyZ0

Learn more about our preclinical efficacy models of chemotherapy-induced peripheral neuropathy and the importance of diversity in preclinical studies. https://hubs.la/Q02y0sZ-0

Preclinical Efficacy Models of Chemotherapy-Induced Peripheral Neuropathy Learn about preclinical efficacy models for Chemotherapy-Induced Peripheral Neuropathy (CIPN) using in vitro and in vivo methods. Understand how these models are crucial for advancing cancer treatment outcomes and alleviating patient suffering.

MD Biosciences offers high throughput screening and high precision target capabilities for preclinical and clinical research. Whether from current or archived studies, MD Biosciences has the capabilities to design studies and biomarker panels that provide maximum value for drug discovery research.

Read more here: https://hubs.la/Q02x-w2D0

Discover the breakthroughs in translational pig models in our latest whitepaper! Pigs are highly valuable research models due to their remarkable resemblance to human physiology. Pigs offer clinically relevant data, short lead times, and competitive pricing. Download the whitepaper to learn more about pig models for pain, inflammation, and wound healing, as well as successful therapeutic studies using the POP model.

https://hubs.la/Q02x4gxk0

MD Biosciences will be at 2024. If you are attending, we'd love to have you visit us at booth 83A.

The RPG group will be presenting at the on May 22-24th. The RPG group is a collaboration between MD Biosciences, Ellegaard Göttingen Minipigs, Novo Nordisk, and the Swedish University of Agricultural Sciences, which aims to address translational approaches to pain management in animals.

Sign up for RPG webinars here: https://hubs.la/Q02wn89g0

Pigs serve as a valuable model for wound healing research, given their remarkable similarity in skin structure to humans. Learn more about our GLP wound healing models in pigs and rodents here: https://hubs.la/Q02nzRj60

Breaking new ground in nerve injury and repair models! MD Biosciences offers preclinical rodent and porcine models for cutting-edge neuropathic pain research, pushing the boundaries of our understanding of pain mechanisms and testing therapeutic applications. Explore our models for peripheral nerve injury and repair, including our translational pig model for peripheral trauma.

Read more about the different nerve injury and repair models: https://hubs.la/Q02mrdvM0

Advancing Pain Research with Translational Pig Models. Pigs share many similarities with humans, including skin innervation, wound healing, and neurological characteristics. These similarities drive clinical significance and pave the way for cutting-edge methods, advanced surgical procedures, and relevant administration routes.

Learn more about why pigs are a favorable translational model.
https://hubs.la/Q02kPxzr0

MD Biosciences is pleased to introduce RealBrain® technology through an exclusive partnership with Tessara Therapeutics.

Tessara Therapeutics has developed a unique cell-based platform, RealBrain®, which models neural micro-tissues for drug discovery. Together, MD Biosciences and Tessara Therapeutics have joined forces in introducing this technology to a broader user base.

RealBrain® provides high modeling accuracy of traditional organoids, but with far greater ease of production, reproducibility and optical clarity.

Learn more: https://hubs.la/Q028nfNg0

MD Biosciences is proud to announce the initiation of a new program to develop a clinically-relevant symptomatic neuroma model in the pig. This effort is supported by the innovation authorities in Israel, and is a joint effort between physicians, neuroscientists, pain scientists, biomarker scientists and expert veterinarians.

To read more about this new model, visit our blog: https://hubs.la/Q025Z6JB0

We're excited to share our new publication in PLOS One. 2-iminobiotin (2-IB) was evaluated in the modified four-vessel (4VO) occlusion model in adult rats, which is an effective model to study the consequences of transient but severe brain ischemia. In the current study we used the 4VO model to investigate whether 2-IB, administered upon reperfusion, can improve cognitive function in a 4VO rat model, mimicking cardiac arrest in adults. The results indicate that 2-IB showed significant improved memory and learning and is a suitable candidate for translation to human studies after OHCA.

Review the full publication: https://hubs.la/Q025P_5H0

MD Biosciences new publication in the Journal of Pain describes a novel P25 wave in the MOG-EAE model. In this study, we assessed evoked potentials as a quantitative marker for in vivo monitoring of nervous system damage. The findings also suggest an increase in p25 amplitude before motor deficits appear, indicating SEP as a predictive marker for disease progression.

https://hubs.la/Q023hCK20

Dr. Sigal Meilin, our Chief Scientific Officer, will be presenting at EFIC next week. Stop by poster Thu-PT-100.

Our Chief Scientific Officer, Dr. Sigal Meilin, will be presenting at at the end of May. If you will be in Prague, please be sure to attend these sessions to discuss the importance of in and using animal models to study and develop therapies for .

https://hubs.la/Q01PF6Px0

Session 1 is on the use of pigs in with a focus on . Dr Suzan Meijs, Dr Hans Jürgen Solinski, and Dr. Avital Schauder will cover the role of pigs in , and transcriptional dissection of somatosensory neurons, and biomarkers in the skin.

Bench to bedside is just a week away. We're introducing our speakers. Kicking off the conference, Peter Vestbjerg and Andres Eskjær Jensen from Ellegaard Gottingen Minipigs will present on the history and use of Gottingen minipigs in biomedical research.

Bench to Bedside conference is less than a month away! MD Biosciences research collaborative is bringing together some of the most innovative minds for a 2-day event. These experts will discuss how translational models, biomarkers and other clinically relevant endpoints, and interactions with clinical physicians will bring new approaches that aid in successful development of pain therapies. Stay tuned as we introduce our speaker line up over the next few weeks.

Register now https://hubs.la/Q01C1NSV0

Bench to Bedside Pain Conference | March 08, 2023 - March 09, 2023 International Pain Conference: Approaches in drug research and development for pain therapies. March 8-9, 2023

The interplay between the nervous system and the immune response highlights the importance of understanding the cellular and attributes that are strongly associated with and . Download our whitepaper to learn more about Inflammatory being explored for valuable information on neurological disease progression and drug efficacy.

https://hubs.la/Q01C1L_n0

Join us for an upcoming conference: Bench to Bedside -> approaches in drug research and development for pain therapies.

We have a fantastic agenda discussing the challenges of developing pain therapies and a focus on translational research using models, biomarkers, and other clinically relevant endpoints. Experts will also present case studies showing novel approaches that will help drug developers advance their pipeline. Register here. https://hubs.la/Q01ycv5G0

Bench to Bedside Pain Conference | March 08, 2023 - March 09, 2023 International Pain Conference: Approaches in drug research and development for pain therapies. March 8-9, 2023

Bench to Bedside Conference -> approaches in drug research and development for pain therapies. Focusing on translational models, biomarkers and other clinically relevant endpoints, and how interactions with clinical physicians will bring new approaches that aid in successful development of pain therapies. Register here. https://hubs.la/Q01wMbXk0

Bench to Bedside Pain Conference | March 08, 2023 - March 09, 2023 International Pain Conference: Approaches in drug research and development for pain therapies. March 8-9, 2023

Just published in Nature: Intraoperative abobotulinumtoxinA alleviates pain after surgery and improves general wellness in a translational animal model.

Using a translational pig model for post-operative pain, this client was able to assess analgesic activity in a model that closely mimics the healing process in humans following surgical procedures. Pain and behavior parameters as well as wound inflammation/healing and mechanistic biomarkers were also evaluated to provide a robust data set.

Read more: https://hubs.la/Q01wgTsS0

How can a study run in young, naive male animals reflect the clinical situation that involves a diversse, older population that have one or more comorbidities? This is an example of the diversity gap in preclinical stroke studies vs clinical studies. MD Biosciences introduces diversity into preclinical studies to better predict the clinical outcome.

https://hubs.la/Q01pS-hB0

The challenge of translating preclinical data to the clinic is often due to the gap in design. Preclinical studies run in single s*x, genetically homogenous animals do not replicate complex human clinical studies. Learn how MD Biosciences, the CNS and pain CRO, introduces diversity in preclinical studies - equipping our partners to better predict clinical outcomes.

https://hubs.la/Q01pSXgZ0

When designing preclinical studies, diversity should be taken into account from tissue culture to large animals. MD Biosciences designs each study and entire programs with the clinic in mind, increasing the translational value of each study.

This free webinar shows 3 examples on how diversity can be incorporated into preclinical studies for better prediction of clinical outcomes.

https://hubs.la/Q01pS-hz0

Webinar: Diversity in Preclinical Studies. Introducing diversity in non-clinical and translational CNS studies for better prediction of clinical outcomes.



https://hubs.la/Q01pS_7F0

Neuroscience is one of the largest and fastest growing focus areas in drug development. Fueling this growth are breakthrough advancements, technologies, and translational biomarkers that have improved our understanding of central nervous system disorders.

Download whitepaper > https://hubs.la/Q01ph2Lw0

development